Evidence map›Paper›PMID 30717586›Full record

ArticleTurkish journal of haematology : official journal of Turkish Society of Haematology2019

Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study

Rafiye Çiftçiler, Hakan Göker, Haluk Demiroğlu, Elifcan Aladağ, Salih Aksu, İbrahim Celalettin Haznedaroğlu, Nilgün Sayınalp, Osman Özcebe, Fatma Tekin, Yahya Büyükaşık

Abstract readComparative Study
In one paragraph

Article in Turkish journal of haematology : official journal of Turkish Society of Haematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rafiye ÇiftçilerHacettepe University Faculty of Medicine, Department of Hematology, Ankara, TurkeyORCID 0000-0001-5687-8531
Hakan GökerHacettepe University Faculty of Medicine, Department of Hematology, Ankara, TurkeyORCID 0000-0002-1039-7756
Haluk DemiroğluHacettepe University Faculty of Medicine, Department of Hematology, Ankara, TurkeyORCID 0000-0002-6790-8748
Elifcan AladağHacettepe University Faculty of Medicine, Department of Hematology, Ankara, TurkeyORCID 0000-0002-1206-9908
Salih AksuHacettepe University Faculty of Medicine, Department of Hematology, Ankara, TurkeyORCID 0000-0003-0634-3808
İbrahim Celalettin HaznedaroğluHacettepe University Faculty of Medicine, Department of Hematology, Ankara, TurkeyORCID 0000-0003-2020-2745
Nilgün SayınalpHacettepe University Faculty of Medicine, Department of Hematology, Ankara, TurkeyORCID 0000-0002-5748-4056
Osman ÖzcebeHacettepe University Faculty of Medicine, Department of Hematology, Ankara, TurkeyORCID 0000-0002-0359-5148
Fatma TekinHacettepe University Faculty of Medicine, Department of Hematology, Ankara, TurkeyORCID 0000-0002-2471-6711
Yahya BüyükaşıkHacettepe University Faculty of Medicine, Department of Hematology, Ankara, TurkeyORCID 0000-0002-2700-295X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment modality for a variety of malignant and non-malignant hematologic disorders. Myeloablative conditioning (MAC) and reduced-intensity conditioning (RIC) regimens could have different clinical outcomes. This purpose of this study was to assess the long-term outcome of MAC versus RIC regimens in patients with acute myeloid leukemia (AML) undergoing allogeneic HSCT. Materials and Methods: We retrospectively compared long-term outcomes with MAC and RIC regimens in patients with AML who underwent allo-HSCT at our tertiary transplantation center. Results: We analyzed survival outcomes after MAC-HSCT versus RICHSCT among 107 adult patients with AML diagnosed from 2001 through 2017. Of those, 44 patients underwent a MAC regimen, whereas 63 patients received a RIC regimen. The median follow-up time was 37 months (range: 6-210) for the entire group. The 3-year overall survival (OS) for RIC and MAC patients was 67% and 60%, respectively (p>0.05). The 3-year progression-free survival (PFS) for RIC and MAC patients was 88% and 77%. In multivariate analysis, the type of conditioning regimen (RIC vs. MAC) did not influence PFS (p=0.24). Acute graft-versus-host disease (GVHD) was seen in five of the RIC patients and 9 of the MAC patients. Chronic GVHD was seen in 16 of the RIC patients and 6 of the MAC patients. There was no significant difference between the two groups in terms of acute GVHD (p=0.089), but there was a significant difference between the two groups in terms of chronic GVHD (p=0.03). Conclusion: This retrospective analysis confirmed that MAC and RIC regimens had a consistently equivalent rate of OS and PFS in AML patients who underwent allo-HSCT. The choice of MAC versus RIC conditioning regimen might be decided on the basis of patient and disease characteristics.

Indexed as

Hematopoietic Stem Cell TransplantationAdultAgedCohort StudiesFemaleGraft vs Host DiseaseHumansLeukemia, Myeloid, AcuteMaleMiddle AgedRetrospective StudiesSurvival RateTransplantation ConditioningTransplantation, HomologousYoung AdultAcute myeloid leukemiaAllogeneic hematopoietic stem cell transplantationRegimen

Identifiers

PMID30717586
PMCPMC6516104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.